Table 1.

Patient characteristics

CharacteristicsNumber of patients%
Total number of patients22 enrolled
20 vaccinated
20 evaluable
Age, y
 Median52
 Range34–69
ER-positive or PR-positive tumor1365
HER2-positive tumor20100
Metastatic disease at diagnosis735
DFI to relapse (months)a
 Mean32
 Median28
 Range0–130
Sites of distant metastasis
 Bone1470
 Liver525
 Lung420
 Lymph node (distant)315
 Brain15
Sum of the longest tumor diameter at study entry
 Mean40.7 mm
 Median24.5 mm
Prior lines of chemotherapy for metastatic disease
 Median1
 Range0–6
 Mean1.25
Prior trastuzumab therapy
 Adjuvant315
 Metastatic1890
Prior lapatinib therapy210
Concurrent endocrine therapy1155
Concurrent bisphosphonate therapy1470

Abbreviations: DFI, disease-free interval; ER, estrogen receptor; PR, progesterone receptor.

  • a13 patients who did not present with metastatic disease at diagnosis.